Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Martine J. Hollestelle"'
Autor:
Martine J. Hollestelle, Ann Helen Kristoffersen, René N. Idema, Piet Meijer, Sverre Sandberg, Moniek P.M. de Maat, Aasne K. Aarsand
Publikováno v:
Clinical Chemistry and Laboratory Medicine. De Gruyter
Objectives The diagnosis and monitoring of bleeding and thrombotic disorders depend on correct haemostatic measurements. The availability of high-quality biological variation (BV) data is important in this context. Many studies have reported BV data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d50edb5e0956b439102966f03810d497
http://www.scopus.com/inward/record.url?scp=85149103435&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85149103435&partnerID=8YFLogxK
Autor:
Michaël V. Lukens, Martine J. Hollestelle, Piet Meijer, Sjef J van de Leur, Nathalie C. V. Péquériaux, Moniek P.M. de Maat, Ryanne A Arisz
Publikováno v:
International Journal of Laboratory Hematology, 44(2), 407-413. Wiley-Blackwell Publishing Ltd
International journal of laboratory hematology, 44(2), 407-413. Wiley
International journal of laboratory hematology, 44(2), 407-413. Wiley
Introduction: The high incidence of thrombotic events in patients with COVID-19 affects health care worldwide and results in an increased workload in haemostasis laboratories due to more frequent testing of D-dimer, haemostatic parameters and anti-Xa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff1ee10f07c075b057ce62f192463c82
https://doi.org/10.1111/ijlh.13760
https://doi.org/10.1111/ijlh.13760
Autor:
Yonah C. Ziemba, Jameel Abdulrehman, Martine J. Hollestelle, Piet Meijer, Elizabeth Plumhoff, Peihong Hsu, Rita Selby
Publikováno v:
Seminars in thrombosis and hemostasis. 48(6)
Accurate diagnosis of von Willebrand disease (VWD) depends on the quality, precision, and variability of the laboratory assays. The North American Specialized Coagulation Laboratory Association (NASCOLA) is a provider of external quality assessment (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e502f95347746247f963ede4008eb30
https://pubmed.ncbi.nlm.nih.gov/36122573
https://pubmed.ncbi.nlm.nih.gov/36122573
Publikováno v:
Seminars in thrombosis and hemostasis. Thieme Medical Publishers
Background Reduced or dysfunctional von Willebrand factor (VWF) may lead to von Willebrand disease (VWD), which is a common inherited bleeding disorder. VWD is classified into three major types: type 1 is a partial quantitative deficiency of VWF, typ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75287341899d9af39f1de8eca23f05a3
https://doi.org/10.1055/s-0042-1757137
https://doi.org/10.1055/s-0042-1757137
Publikováno v:
Journal of Thrombosis and Haemostasis. 18:2613-2621
Introduction One of the main advantages of using anti-Xa instead of activated partial thromboplastin time in monitoring of unfractionated heparin (UFH) therapy relies on its hypothesized standardization, with a unique therapeutic range defined to be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e1f2d446da9b402d68611c41660f9d0
https://doi.org/10.1111/jth.14969
https://doi.org/10.1111/jth.14969
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 58:1921-1930
Objectives Chromogenic anti-activated factor X (FXa) assays are currently the “gold standard” for monitoring indirect anticoagulants. However, anti-FXa has been shown to vary according to the choice of reagents. In the present study, the performa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa853255b024bf5e99a417c698a48db
https://doi.org/10.1515/cclm-2020-0130
https://doi.org/10.1515/cclm-2020-0130
Autor:
Jameel Abdulrehman, Peihong Hsu, Piet Meijer, Elizabeth A. Plumhoff, Rita Selby, Elizabeth M. Van Cott, Yonah Ziemba, Martine J Hollestelle
Publikováno v:
Haemophilia. 27
Background Laboratory diagnosis of von Willebrand Disease (VWD) is complex. Reliance on laboratory testing can be problematic as different VWD screening panels, assays and methodologies can produce analytic variability in test results. Objectives To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72623bf7dd400229be7bbe64f83bcd25
https://doi.org/10.1111/hae.14397
https://doi.org/10.1111/hae.14397
Autor:
Martine J Hollestelle, Ka Wai Lai, Marcel van Deuren, Peter J Lenting, Philip G de Groot, Tom Sprong, Niels Bovenschen
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24216 (2011)
Von Willebrand factor (VWF) is a pro-hemostatic multimeric plasma protein that promotes platelet aggregation and stabilizes coagulation factor VIII (FVIII) in plasma. The metalloproteinase ADAMTS13 regulates the platelet aggregation function of VWF v
Externí odkaz:
https://doaj.org/article/302eb4089977461eb7ca781cb88986a5
Autor:
Piet Meijer, Martine J Hollestelle
Publikováno v:
British journal of haematologyReferences. 188(3)
There is limited information regarding the performance of tests for direct oral anticoagulants (DOACs). To generate more knowledge, the accuracy of DOAC tests were evaluated using external quality assessment data from multiple years. This data demons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47bde310b593705bd82c8d5964fc06d7
https://pubmed.ncbi.nlm.nih.gov/31475356
https://pubmed.ncbi.nlm.nih.gov/31475356
Autor:
Timothy A. L. Woods, Roslyn Bonar, Soma Mohammed, Emmanuel J. Favaloro, Piet Meijer, Muriel Meiring, Ian Jennings, Martine J Hollestelle
Publikováno v:
Thrombosis research. 166
Introduction von Willebrand disease (VWD), the most common inherited bleeding disorder, is due to deficiencies/defects in von Willebrand factor (VWF). Effective diagnosis requires testing for FVIII, VWF antigen and one or more VWF ‘activity’ assa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8fe666c7f716a1a0147e29175c4a7c8
https://pubmed.ncbi.nlm.nih.gov/29727738
https://pubmed.ncbi.nlm.nih.gov/29727738